203 related articles for article (PubMed ID: 24444656)
1. Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.
Sharma S; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
Mol Oncol; 2014 May; 8(3):469-82. PubMed ID: 24444656
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.
Sharma S; Zeng JY; Zhuang CM; Zhou YQ; Yao HP; Hu X; Zhang R; Wang MH
Mol Cancer Ther; 2013 May; 12(5):725-36. PubMed ID: 23468529
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells.
Zeng JY; Sharma S; Zhou YQ; Yao HP; Hu X; Zhang R; Wang MH
Mol Cancer Ther; 2014 Jan; 13(1):37-48. PubMed ID: 24233399
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
5. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.
Shi JJ; Chen SM; Guo CL; Li YX; Ding J; Meng LH
Acta Pharmacol Sin; 2018 Aug; 39(8):1338-1346. PubMed ID: 29345254
[TBL] [Abstract][Full Text] [Related]
6. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
Huang S; Yang ZJ; Yu C; Sinicrope FA
J Biol Chem; 2011 Nov; 286(46):40002-12. PubMed ID: 21949121
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
12. AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression.
Chen Y; Lee CH; Tseng BY; Tsai YH; Tsai HW; Yao CL; Tseng SH
Anticancer Res; 2018 Mar; 38(3):1445-1454. PubMed ID: 29491070
[TBL] [Abstract][Full Text] [Related]
13. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N
Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964
[TBL] [Abstract][Full Text] [Related]
14. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
[TBL] [Abstract][Full Text] [Related]
15. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
16. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
18. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.
Wu CC; Weng CS; Hsu YT; Chang CL
Taiwan J Obstet Gynecol; 2019 Jan; 58(1):145-152. PubMed ID: 30638469
[TBL] [Abstract][Full Text] [Related]
20. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]